2026-2034年全球基因組學市場規模、佔有率、趨勢和成長分析報告（癌症治療領域）

全球癌症治療基因組學市場預計將從2025年的284.2億美元成長至2034年的1,128.7億美元，2026年至2034年的複合年成長率（CAGR）為16.56%。這個市場擴張的原因在於基因組學在闡明癌症發展機制、識別基因突變和製定治療策略方面的重要性日益凸顯。基因組檢測使醫療專業人員能夠檢查腫瘤特徵並識別可能影響疾病進展的分子水平變化。對精準腫瘤學日益成長的需求、定序技術的進步以及人們對個人化癌症治療認知的不斷提高，都在推動這項技術的應用。醫療機構正在將基因組資訊整合到診斷和治療流程中，以改善臨床決策。這些進步正在強化基因組分析在癌症檢測、治療選擇和疾病監測中的作用。

市場成長的驅動力來自次世代定序技術的進步、定序成本的降低以及癌症研究投入的增加。製藥公司正在利用基因組數據來識別潛在的藥物標靶，並支持標靶治療的開發。同時，醫院、診斷實驗室和研究機構也不斷提升其分子譜分析能力。生物技術公司與醫療服務提供者之間日益密切的合作也推動了創新。人工智慧（AI）和生物資訊學工具的整合正在改善對複雜基因組資料集的解讀，幫助研究人員識別具有臨床意義的突變並探索新療法的潛力。

預計基因組檢測的普及、數據分析技術的進步以及標靶癌症療法的持續發展將推動該市場的未來成長。液態生物檢體和全面基因組分析技術的進步有望實現創傷性較小的檢測和更頻繁的疾病監測。將基因組資訊進一步整合到臨床指引中，將進一步強化其在常規腫瘤診療中的作用。然而，保險報銷、資料隱私、檢測成本以及專科服務取得方面的差異等挑戰仍將需要重點關注。解決這些障礙可望拓展基因體學在各類癌症及醫療服務的應用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面審查，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球基因體學市場在癌症治療的應用：依產品分類

• 市場分析、洞察與預測
• 裝置
• 消耗品
• 服務

第5章：全球基因體學市場在癌症治療的應用

• 市場分析、洞察與預測
• 診斷
• 個人化醫療
• 藥物發現與開發
• 調查

第6章 全球基因體學市場在癌症治療的應用：依技術分類

• 市場分析、洞察與預測
• 基因測序
• PCR
• 微陣列
• 核酸萃取與純化
• 其他

第7章 全球基因體學市場在癌症治療的應用：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Illumina
  • Thermo Fisher Scientific
  • Foundation Medicine
  • Guardant Health
  • Natera
  • Tempus AI
  • Exact Sciences
  • Caris Life Sciences
  • Invitae
  • NeoGenomics
  • QIAGEN
  • Roche
  • Agilent Technologies
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • Personalis
  • Burning Rock Biotech
  • BGI Genomics
  • GeneCentric Therapeutics
  • GRAIL

The global genomics in cancer care market size is expected to reach USD 112.87 Billion in 2034 from USD 28.42 Billion in 2025, growing at a CAGR of 16.56% during 2026-2034.This market is expanding as genomics becomes increasingly important in understanding cancer development, identifying genetic alterations, and guiding treatment decisions. Genomic testing enables healthcare professionals to examine tumor characteristics and identify molecular changes that may influence disease progression. Growing demand for precision oncology, improvements in sequencing technologies, and increasing awareness of personalized cancer treatment are supporting adoption. Healthcare institutions are incorporating genomic information into diagnostic and treatment workflows to improve clinical decision-making. These developments are strengthening the role of genomic analysis in cancer detection, treatment selection, and disease monitoring.

Market growth is driven by advancements in next-generation sequencing, declining sequencing costs, and increasing investments in cancer research. Pharmaceutical companies are using genomic data to identify potential drug targets and support the development of targeted therapies. Meanwhile, hospitals, diagnostic laboratories, and research institutions are expanding their capabilities to perform molecular profiling. Growing collaborations between biotechnology companies and healthcare providers are also supporting innovation. The integration of artificial intelligence and bioinformatics tools is improving the interpretation of complex genomic datasets, helping researchers identify clinically relevant mutations and investigate new treatment opportunities.

The future of this market is expected to be influenced by broader access to genomic testing, improved data analysis, and the continued development of targeted cancer therapies. Advances in liquid biopsy and comprehensive genomic profiling may support less invasive testing and more frequent disease monitoring. Greater integration of genomic information into clinical guidelines could further strengthen its role in routine oncology care. However, challenges related to reimbursement, data privacy, testing costs, and unequal access to specialized services will remain important considerations. Addressing these barriers could help expand the application of genomics across different cancer types and healthcare settings.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Instruments
• Consumables
• Services

By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

By Technology

• Genome Sequencing
• PCR
• Microarrays
• Nucleic Acid Extraction and Purification
• Other

COMPANIES PROFILED

• Illumina, Thermo Fisher Scientific, Foundation Medicine, Guardant Health, Natera, Tempus AI, Exact Sciences, Caris Life Sciences, Invitae, NeoGenomics, QIAGEN, Roche, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, Personalis, Burning Rock Biotech, BGI Genomics, GeneCentric Therapeutics, GRAIL

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOMICS IN CANCER CARE MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOMICS IN CANCER CARE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOMICS IN CANCER CARE MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology
• 6.2. Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Microarrays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Nucleic Acid Extraction and Purification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOMICS IN CANCER CARE MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By Technology
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By Technology
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By Technology
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By Technology
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By Technology
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENOMICS IN CANCER CARE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Illumina
  • 9.2.2 Thermo Fisher Scientific
  • 9.2.3 Foundation Medicine
  • 9.2.4 Guardant Health
  • 9.2.5 Natera
  • 9.2.6 Tempus AI
  • 9.2.7 Exact Sciences
  • 9.2.8 Caris Life Sciences
  • 9.2.9 Invitae
  • 9.2.10 NeoGenomics
  • 9.2.11 QIAGEN
  • 9.2.12 Roche
  • 9.2.13 Agilent Technologies
  • 9.2.14 Bio-Rad Laboratories
  • 9.2.15 F. Hoffmann-La Roche
  • 9.2.16 Personalis
  • 9.2.17 Burning Rock Biotech
  • 9.2.18 BGI Genomics
  • 9.2.19 GeneCentric Therapeutics
  • 9.2.20 GRAIL